ABUS
Price
$4.38
Change
-$0.09 (-2.01%)
Updated
Sep 16, 11:11 AM (EDT)
51 days until earnings call
DOMH
Price
$1.88
Change
-$0.04 (-2.08%)
Updated
Sep 13 closing price
60 days until earnings call
Ad is loading...

ABUS vs DOMH

Header iconABUS vs DOMH Comparison
Open Charts ABUS vs DOMHBanner chart's image
Arbutus Biopharma
Price$4.38
Change-$0.09 (-2.01%)
Volume$1.4K
CapitalizationN/A
Dominari Holdings
Price$1.88
Change-$0.04 (-2.08%)
Volume$3.46K
CapitalizationN/A
View a ticker or compare two or three
ABUS vs DOMH Comparison Chart
Loading...
ABUS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
DOMH
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
ABUS vs. DOMH commentary
Sep 16, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABUS is a Buy and DOMH is a StrongBuy.

COMPARISON
Comparison
Sep 16, 2024
Stock price -- (ABUS: $4.47 vs. DOMH: $1.88)
Brand notoriety: ABUS and DOMH are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABUS: 102% vs. DOMH: 45%
Market capitalization -- ABUS: $843.86M vs. DOMH: $11.77M
ABUS [@Biotechnology] is valued at $843.86M. DOMH’s [@Biotechnology] market capitalization is $11.77M. The market cap for tickers in the [@Biotechnology] industry ranges from $606.91B to $0. The average market capitalization across the [@Biotechnology] industry is $3.05B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABUS’s FA Score shows that 0 FA rating(s) are green whileDOMH’s FA Score has 1 green FA rating(s).

  • ABUS’s FA Score: 0 green, 5 red.
  • DOMH’s FA Score: 1 green, 4 red.
According to our system of comparison, ABUS is a better buy in the long-term than DOMH.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABUS’s TA Score shows that 4 TA indicator(s) are bullish while DOMH’s TA Score has 5 bullish TA indicator(s).

  • ABUS’s TA Score: 4 bullish, 4 bearish.
  • DOMH’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, DOMH is a better buy in the short-term than ABUS.

Price Growth

ABUS (@Biotechnology) experienced а -1.76% price change this week, while DOMH (@Biotechnology) price change was +4.17% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.21%. For the same industry, the average monthly price growth was +4.35%, and the average quarterly price growth was -1.90%.

Reported Earning Dates

ABUS is expected to report earnings on Nov 06, 2024.

DOMH is expected to report earnings on Nov 15, 2024.

Industries' Descriptions

@Biotechnology (+2.21% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABUS($844M) has a higher market cap than DOMH($11.8M). ABUS YTD gains are higher at: 78.800 vs. DOMH (-27.606). DOMH has higher annual earnings (EBITDA): -14.02M vs. ABUS (-75.48M). ABUS has more cash in the bank: 142M vs. DOMH (12.1M). ABUS has less debt than DOMH: ABUS (1.6M) vs DOMH (3.24M). ABUS has higher revenues than DOMH: ABUS (10.1M) vs DOMH (9.51M).
ABUSDOMHABUS / DOMH
Capitalization844M11.8M7,153%
EBITDA-75.48M-14.02M538%
Gain YTD78.800-27.606-285%
P/E RatioN/AN/A-
Revenue10.1M9.51M106%
Total Cash142M12.1M1,174%
Total Debt1.6M3.24M49%
FUNDAMENTALS RATINGS
ABUS vs DOMH: Fundamental Ratings
ABUS
DOMH
OUTLOOK RATING
1..100
741
VALUATION
overvalued / fair valued / undervalued
1..100
67
Overvalued
11
Undervalued
PROFIT vs RISK RATING
1..100
46100
SMR RATING
1..100
9797
PRICE GROWTH RATING
1..100
3556
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DOMH's Valuation (11) in the null industry is somewhat better than the same rating for ABUS (67) in the Biotechnology industry. This means that DOMH’s stock grew somewhat faster than ABUS’s over the last 12 months.

ABUS's Profit vs Risk Rating (46) in the Biotechnology industry is somewhat better than the same rating for DOMH (100) in the null industry. This means that ABUS’s stock grew somewhat faster than DOMH’s over the last 12 months.

ABUS's SMR Rating (97) in the Biotechnology industry is in the same range as DOMH (97) in the null industry. This means that ABUS’s stock grew similarly to DOMH’s over the last 12 months.

ABUS's Price Growth Rating (35) in the Biotechnology industry is in the same range as DOMH (56) in the null industry. This means that ABUS’s stock grew similarly to DOMH’s over the last 12 months.

ABUS's P/E Growth Rating (100) in the Biotechnology industry is in the same range as DOMH (100) in the null industry. This means that ABUS’s stock grew similarly to DOMH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABUSDOMH
RSI
ODDS (%)
Bearish Trend 4 days ago
78%
Bearish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 4 days ago
90%
Momentum
ODDS (%)
Bullish Trend 4 days ago
85%
Bullish Trend 4 days ago
80%
MACD
ODDS (%)
Bullish Trend 4 days ago
77%
Bullish Trend 4 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
79%
Bullish Trend 4 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 4 days ago
83%
Advances
ODDS (%)
Bullish Trend 6 days ago
80%
Bullish Trend 8 days ago
78%
Declines
ODDS (%)
Bearish Trend 19 days ago
78%
N/A
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
80%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bullish Trend 4 days ago
81%
Bearish Trend 4 days ago
86%
View a ticker or compare two or three
Ad is loading...
ABUS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
DOMH
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PAGHX88.461.15
+1.32%
Permanent Portfolio Aggressive Growth C
IVKSX20.530.19
+0.93%
VY® Invesco Comstock S
VFSNX232.871.53
+0.66%
Vanguard FTSE All-Wld ex-US SmCp Idx Ins
IVFLX4.000.02
+0.50%
Federated Hermes Intl Strat Val Div R6
FTANX12.110.04
+0.33%
Fidelity Asset Manager 30%

DOMH and

Correlation & Price change

A.I.dvisor indicates that over the last year, DOMH has been loosely correlated with AXON. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if DOMH jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DOMH
1D Price
Change %
DOMH100%
-2.34%
AXON - DOMH
36%
Loosely correlated
-1.27%
ARDX - DOMH
31%
Poorly correlated
+1.45%
MDGL - DOMH
28%
Poorly correlated
+3.00%
ABUS - DOMH
27%
Poorly correlated
+3.71%
VBIVQ - DOMH
27%
Poorly correlated
-5.88%
More